SCM
NRIX icon

Sterling Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Sterling Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1K Sell
703
-2,673
-79% -$45.5K ﹤0.01% 1958
2026
Q1 		$52.3K Sell
3,376
-2,401
-42% -$39.8K ﹤0.01% 1620
2025
Q4 		$110K Buy
5,777
+575
+11% +$8.26K ﹤0.01% 1495
2025
Q3 		$48.1K Buy
5,202
+3,167
+156% +$32.9K ﹤0.01% 1763
2025
Q2 		$23.2K Buy
2,035
+1,581
+348% +$17.1K ﹤0.01% 1739
2025
Q1 		$5.39K Sell
454
-279
-38% -$4.67K ﹤0.01% 2129
2024
Q4 		$13.8K Buy
733
+624
+572% +$14.3K ﹤0.01% 2007
2024
Q3 		$2.45K Buy
+109
New +$2.47K ﹤0.01% 2092

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sterling Capital Management's NRIX Position: Q2 2026 in Review

Sterling Capital Management reduced its Nurix Therapeutics (NRIX) stake by 79% in Q2 2026, selling an estimated $45.5K and leaving 703 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1958.

Sterling Capital Management first reported a position in NRIX in Q3 2024 and has held it in 8 quarters since. The position peaked at $110K in Q4 2025. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Sterling Capital Management held 703 shares of Nurix Therapeutics worth $17.1K as of Q2 2026.
  • Sterling Capital Management sold 2,673 Nurix Therapeutics shares in Q2 2026, an estimated $45.5K.
  • Nurix Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1958 holding.
  • Sterling Capital Management first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Nurix Therapeutics position peaked at $110K in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.